文献速递临床试验与 GCP医学人工智能与信息学流行病学与生物统计

临床决策支持联合审计与反馈对冠状动脉造影患者急性肾损伤预防的影响:一项随机临床试验

Effect of Clinical Decision Support With Audit and Feedback on Prevention of Acute Kidney Injury in Patients Undergoing Coronary Angiography: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2022-01-01

在加拿大阿尔伯塔省3个心导管室开展阶梯楔形整群随机临床试验,纳入34名心脏科医生实施的7820例次手术(7106名患者)。干预期急性肾损伤发生率为7.2%,对照期为8.6%,时间校正后绝对风险降低2.3%;干预期造影剂过量使用比例和静脉补液不足比例均降低。

要点

  • 干预期急性肾损伤发生率为7.2%,对照期为8.6%,组间差异为-2.3%(95%CI -0.6%至-4.1%)。
  • 干预期造影剂过量使用比例降至38.1%,对照期为51.7%,组间差异为-12.0%。
  • 干预期静脉补液不足比例降至60.8%,对照期为75.1%,组间差异为-15.8%。

核心结论

  • 在被随机分配接受包含临床决策支持与审计反馈干预的心脏科医生处,干预期接受冠状动脉手术的患者发生急性肾损伤的可能性低于对照期患者,时间校正后绝对风险降低2.3%。
  • 该干预是否在本研究环境之外显示有效性需进一步研究。

研究设计与样本

  • 在加拿大阿尔伯塔省3个心导管室开展的阶梯楔形整群随机临床试验,所有侵入性心脏科医生被随机分配至2018年1月至2019年9月间的不同干预开始日期。
  • 纳入标准为年龄18岁及以上、接受非急诊冠状动脉造影或经皮冠状动脉介入治疗(PCI)或两者、未接受透析、预测急性肾损伤风险大于5%的患者。
  • 34名医生共实施7820例次手术,涉及7106名符合纳入标准的患者;参与者随访于2020年11月结束。
  • 干预组包括31名医生,实施4327例次手术,涉及4032名患者(平均年龄70.3岁[SD 10.7],女性1384名[32.0%]);对照组包括34名医生,实施3493例次手术,涉及3251名患者(平均年龄70.2岁[SD 10.8],女性1151名[33.0%])。

主要发现

  • 干预期急性肾损伤发生率为7.2%(4327例次手术中310例事件),对照期为8.6%(3493例次手术中299例事件),组间差异为-2.3%(95%CI -0.6%至-4.1%),比值比(OR)为0.72(95%CI 0.56至0.93),P=0.01。
  • 12项预设次要结局中有8项显示无显著差异。
  • 干预期造影剂过量使用的比例降至38.1%,对照期为51.7%,组间差异为-12.0%(95%CI -14.4%至-9.4%),OR为0.77(95%CI 0.65至0.90),P=0.002。
  • 干预期符合条件患者中静脉补液不足的比例降至60.8%,对照期为75.1%,组间差异为-15.8%(95%CI -19.7%至-12.0%),OR为0.68(95%CI 0.53至0.87),P=0.002。
  • 主要不良心血管事件或主要不良肾脏事件在组间无显著差异。

关键数值与推荐

  • 干预措施包括教育外展、关于造影剂用量和血流动力学指导的静脉补液目标的计算机化临床决策支持,以及审计与反馈。
  • 对照(干预前)期,心脏科医生提供常规护理,未接受干预。
  • 主要结局为急性肾损伤;12项次要结局包括造影剂用量、静脉补液和主要不良心血管及肾脏事件。
  • 分析使用时间校正模型。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 该干预是否在本研究环境之外显示有效性需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Contrast-associated acute kidney injury (AKI) is a common complication of coronary angiography and percutaneous coronary intervention (PCI) that has been associated with high costs and adverse long-term outcomes. OBJECTIVE: To determine whether a multifaceted intervention is effective for the prevention of AKI after coronary angiography or PCI. DESIGN, SETTING, AND PARTICIPANTS: A stepped-wedge, cluster randomized clinical trial was conducted in Alberta, Canada, that included all invasive cardiologists at 3 cardiac catheterization laboratories who were randomized to various start dates for the intervention between January 2018 and September 2019. Eligible patients were aged 18 years or older who underwent nonemergency coronary angiography, PCI, or both; who were not undergoing dialysis; and who had a predicted AKI risk of greater than 5%. Thirty-four physicians performed 7820 procedures among 7106 patients who met the inclusion criteria. Participant follow-up ended in November 2020. INTERVENTIONS: During the intervention period, cardiologists received educational outreach, computerized clinical decision support on contrast volume and hemodynamic-guided intravenous fluid targets, and audit and feedback. During the control (preintervention) period, cardiologists provided usual care and did not receive the intervention. MAIN OUTCOMES AND MEASURES: The primary outcome was AKI. There were 12 secondary outcomes, including contrast volume, intravenous fluid administration, and major adverse cardiovascular and kidney events. The analyses were conducted using time-adjusted models. RESULTS: Of the 34 participating cardiologists who were divided into 8 clusters by practice group and center, the intervention group included 31 who performed 4327 procedures among 4032 patients (mean age, 70.3 [SD, 10.7] years; 1384 were women [32.0%]) and the control group included 34 who performed 3493 procedures among 3251 patients (mean age, 70.2 [SD, 10.8] years; 1151 were women [33.0%]). The incidence of AKI was 7.2% (310 events after 4327 procedures) during the intervention period and 8.6% (299 events after 3493 procedures) during the control period (between-group difference, -2.3% [95% CI, -0.6% to -4.1%]; odds ratio [OR], 0.72 [95% CI, 0.56 to 0.93]; P = .01). Of 12 prespecified secondary outcomes, 8 showed no significant difference. The proportion of procedures in which excessive contrast volumes were used was reduced to 38.1% during the intervention period from 51.7% during the control period (between-group difference, -12.0% [95% CI, -14.4% to -9.4%]; OR, 0.77 [95% CI, 0.65 to 0.90]; P = .002). The proportion of procedures in eligible patients in whom insufficient intravenous fluid was given was reduced to 60.8% during the intervention period from 75.1% during the control period (between-group difference, -15.8% [95% CI, -19.7% to -12.0%]; OR, 0.68 [95% CI, 0.53 to 0.87]; P = .002). There were no significant between-group differences in major adverse cardiovascular events or major adverse kidney events. CONCLUSIONS AND RELEVANCE: Among cardiologists randomized to an intervention including clinical decision support with audit and feedback, patients undergoing coronary procedures during the intervention period were less likely to develop AKI compared with those treated during the control period, with a time-adjusted absolute risk reduction of 2.3%. Whether this intervention would show efficacy outside this study setting requires further investigation. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03453996.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. James MT, Har BJ, Tyrrell BD, et al. Effect of Clinical Decision Support With Audit and Feedback on Prevention of Acute Kidney Injury in Patients Undergoing Coronary Angiography: A Randomized Clinical Trial. JAMA. 2022. PMID: 36066520. doi:10.1001/jama.2022.13382

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。